Cleveland Clinic Agrees to Limit Gender-Affirming Care for Minors in Settlement

Cleveland Clinic, one of the U.S.’s leading healthcare institutions, has agreed to restrict access to puberty blockers and certain hormone treatments for transgender minors as part of a settlement with the Ohio attorney general’s office, according to a court filing. The agreement, which resolves a lawsuit alleging violations of state medical licensing laws, prohibits the clinic from providing “gender-affirming procedures” without prior approval from an external ethics review board.

What Does the Settlement Entail?

The settlement, filed in Cuyahoga County Common Pleas Court, requires Cleveland Clinic to halt the use of puberty blockers and hormone therapies for minors under 18 unless a multidisciplinary panel of medical experts approves the treatment. The clinic also agreed to limit other procedures described as “gender-affirming care,” though the exact scope of these restrictions remains unclear. Ohio Attorney General Dave Yost’s office stated the agreement “ensures compliance with state medical standards and protects patients from unproven interventions.”

Cleveland Clinic did not immediately respond to requests for comment. However, a spokesperson for the institution previously emphasized its commitment to “evidence-based care” for transgender patients, citing guidelines from the American Academy of Pediatrics and the Endocrine Society.

Context: Legal and Medical Debates Over Gender-Affirming Care

The settlement reflects broader national legal and ethical debates over the use of puberty blockers and hormones for transgender youth. Several states, including Texas and Idaho, have banned such treatments for minors, citing concerns about long-term health effects and the need for more research. In contrast, medical organizations like the World Health Organization and the American Medical Association endorse gender-affirming care as a critical component of adolescent healthcare.

Ohio’s attorney general’s office argued in its lawsuit that Cleveland Clinic’s practices “lacked proper oversight” and risked “harm to vulnerable patients.” The state’s medical board has previously flagged concerns about the use of puberty blockers, which can delay puberty but are not reversible. Critics of the settlement, including LGBTQ+ advocacy groups, warn that restrictions could limit access to life-saving care for transgender youth.

Implications for Patients and Providers

The agreement could set a precedent for how healthcare institutions navigate state regulations on gender-affirming care. Providers in Ohio may now face stricter scrutiny when evaluating requests for puberty blockers or hormones for minors. Dr. Sarah M. Wilson, a pediatric endocrinologist at the University of Cincinnati, noted that “the balance between patient autonomy and medical oversight is delicate, and this settlement highlights the need for clear, consistent guidelines.”

For patients, the restrictions may create barriers to timely care. A 2023 study in the *Journal of Adolescent Health* found that transgender adolescents who received puberty blockers reported significantly lower rates of depression and suicidal ideation compared to those who did not. However, the study also emphasized the importance of individualized medical assessments.

What Happens Next?

The settlement does not resolve the broader legal challenges facing gender-affirming care in Ohio. A separate lawsuit filed by LGBTQ+ advocacy groups argues that the state’s restrictions on puberty blockers violate the U.S. Constitution’s Equal Protection Clause. The case is pending in federal court. Meanwhile, Cleveland Clinic’s compliance with the agreement will likely be monitored by the Ohio Medical Board.

As the debate continues, the case underscores the complex interplay between medical ethics, legal frameworks, and patient rights. For now, the settlement represents a significant shift in how one major healthcare system approaches gender-affirming care for minors.

Key Takeaways

• Cleveland Clinic agreed to limit puberty blockers and hormone treatments for minors under a settlement with Ohio’s attorney general.
• The agreement requires external approval for gender-affirming procedures, raising questions about access and oversight.
• Legal and medical debates over these treatments remain unresolved, with conflicting state laws and clinical guidelines.